Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: MOUNJARO
Published 2026-03-24 · Last reviewed 2026-03-31 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Mounjaro is a once-weekly injectable form of tirzepatide, a dual GIP/GLP-1 receptor agonist indicated for type 2 diabetes (label).
It is not a psychiatric medication. In psychiatric practice, it is most often considered when diabetes/obesity complicate care or when cardiometabolic risk from weight-gain–promoting psychotropics is clinically limiting (clinical).
A high-impact practical warning is reduced efficacy of oral hormonal contraceptives during initiation and dose escalation due to delayed gastric emptying; contraception counseling should be explicit and proactive (label).
The compare view, evidence feed, and print page help compare titration schedules and monitoring themes.
In psychiatric populations, feasibility often depends on coverage, follow-up capacity during titration, and coordination across prescribers (especially when diabetes medications need adjustment). GI tolerability and hydration planning can be critical to avoid destabilizing adherence to psychotropics (clinical).
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Clinically it improves glycemic control and supports weight loss through incretin-based metabolic signaling, appetite effects, and delayed gastric emptying (label/clinical).
In mental health care, the most common rationale is metabolic risk reduction while maintaining psychiatric stability and medication adherence (clinical).
Consider coordination with primary care/endocrinology for diabetes and cardiovascular risk management; avoid siloed medication changes (clinical).